Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25378460 | 0.86 | GRM4 (0.45) | HTTLMNAHPGDPDE10ASMN1; SMN2 | |
| SCHEMBL25379789 | 0.86 | KDM4E (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL25374628 | 0.83 | AHR (0.39) | HTTLMNAHPGDMAPTRAB9A | |
| SCHEMBL25379048 | 0.82 | LMNA (0.35) | HTTLMNAHPGDNPBWR1 | |
| SCHEMBL25379560 | 0.82 | TRPV1 (0.36) | HTTLMNAHPGDALDH1A1MAPT | |
| SCHEMBL25375690 | 0.82 | SMN1; SMN2 (0.41) | HTTLMNAHPGDNPC1ALDH1A1 | |
| SCHEMBL25377702 | 0.82 | RAB9A (0.42) | HTTLMNAHPGDNPC1ALDH1A1 | |
| SCHEMBL25377593 | 0.81 | LTA4H (0.36) | HTTLMNAHPGDALDH1A1MAPT | |
| SCHEMBL25377456 | 0.81 | MAPT (0.40) | HTTLMNAHPGDMAPTPDE10A | |
| SCHEMBL30482531 | 0.81 | LTA4H (0.36) | HTTLMNAHPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |